AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2017
May 5, 2017
30016_dirs_2017-05-05_6945d0c8-05e3-4792-b046-2d09ec4dc1d5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2017-05-03
Reporting Person: HENDERSON REBECCA M (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-05-04 | Common Stock | M | 6602 | $38.7950 | Acquired | 21552 | Direct |
| 2017-05-04 | Common Stock | S | 1700 | $159.9485 | Disposed | 19852 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-05-03 | Deferred Stock Unit | $ | A | 289 | Acquired | Common Stock (289) | Direct | |
| 2017-05-03 | Non-Qualified Stock Option (right-to-buy) | $160.28 | A | 3046 | Acquired | 2027-05-02 | Common Stock (3046) | Direct |
| 2017-05-04 | Non-Qualified Stock Option (right-to-buy) | $38.7950 | M | 6602 | Disposed | 2018-02-13 | Common Stock (6602) | Direct |
Footnotes
F1: Represents the weighted average sales price of the shares sold ranging from a low of $159.9110 to a high of $159.9718 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F2: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.
F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018.
F4: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,301 shares on February 14, 2012, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split").? The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F5: Not applicable.